December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genmab A/S

< Previous 1 2 3 4 Next >
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Financial Results for the First Quarter of 2023
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Initiation of Share Buy-Back Program
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Publishes 2022 Annual Report
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Financial Results for the First Nine Months of 2022
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Improves Its 2022 Financial Guidance
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
From Genmab A/S
Via GlobeNewswire
News headline image
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
News headline image
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers ABBV GMAB
News headline image
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB SGEN
News headline image
Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
From Genmab A/S
Via Business Wire
Tickers ABBV GMAB
News headline image
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Genmab A/S
Via Business Wire
Tickers GMAB SGEN
News headline image
Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
From Genmab A/S
Via Business Wire
Tickers GMAB
News headline image
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB SGEN
News headline image
Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
From Genmab A/S
Via Business Wire
Tickers ABBV GMAB
News headline image
Genmab and Bolt Biotherapeutics Announce Oncology Research and Development Collaboration
From Genmab A/S
Via Business Wire
Tickers GMAB
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.